TFAP2A and lung cancer: Our findings, for the first time, demonstrate that AP2 is an important transcription factor driving USP22 gene expression, promoting the progression of NSCLC in part by enhancing USP22 expression, which will further facilitate the understanding of the USP22 network and the targeted treatment of lung cancer.